Cubist Systematic Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cubist Systematic Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,800	Closed	-$264K	–	3027
2025 Q2	$264K	Buy	+4,800	New	+$283K	﹤0.01%	2495
2024 Q4	–	Sell	-10,900	Closed	-$766K	–	2997
2024 Q3	$766K	Buy	10,900 +7,900	+263%	+$660K	﹤0.01%	1989
2024 Q2	$247K	Hold	3,000	–	–	﹤0.01%	2431
2024 Q1	$262K	Hold	3,000	–	–	﹤0.01%	2943
2023 Q4	$289K	Buy	+3,000	New	+$265K	﹤0.01%	2810

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Cubist Systematic Strategies's BMRN Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 165,408 shares — an estimated $9.74M sold.

Cubist Systematic Strategies first reported a position in BMRN in Q2 2014 and held it in 40 quarters. The position peaked at $17.3M in Q2 2023. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

Cubist Systematic Strategies reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 165,408 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $9.74M.
Cubist Systematic Strategies first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 40 quarters.
Cubist Systematic Strategies's BioMarin Pharmaceuticals position peaked at $17.3M in Q2 2023.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.